KRMD - Repro-Med Systems Inc Stock Price, Fair Value and News

2.20USD+0.06 (+2.80%)Market Closed

Market Summary

USD2.20+0.06

Market Closed

2.80%

KRMD Stock Price

View Fullscreen

KRMD RSI Chart

KRMD Valuation

Market Cap

100.6M

Price/Earnings (Trailing)

-7.32

Price/Sales (Trailing)

3.53

EV/EBITDA

-10.06

Price/Free Cashflow

-20.55

KRMD Price/Sales (Trailing)

KRMD Profitability

EBT Margin

-34.27%

Return on Equity

-67.51%

Return on Assets

-48.28%

Free Cashflow Yield

-4.87%

KRMD Fundamentals

KRMD Revenue

Revenue (TTM)

28.5M

Rev. Growth (Yr)

-2.16%

Rev. Growth (Qtr)

2.61%

KRMD Earnings

Earnings (TTM)

-13.7M

Earnings Growth (Yr)

-277.7%

Earnings Growth (Qtr)

-445.66%

Breaking Down KRMD Revenue

Last 7 days

-0.5%

Last 30 days

1.9%

Last 90 days

1.4%

Trailing 12 Months

-47.8%

How does KRMD drawdown profile look like?

KRMD Financial Health

Current Ratio

4.55

KRMD Investor Care

Shares Dilution (1Y)

0.86%

Diluted EPS (TTM)

-0.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	29.0M	29.4M	28.7M	28.5M
2022	24.3M	25.3M	27.0M	27.9M
2021	23.3M	21.1M	21.1M	23.5M
2020	24.5M	26.9M	26.3M	24.2M
2019	18.3M	19.1M	21.2M	23.2M
2018	16.6M	17.3M	18.0M	17.4M
2017	12.4M	13.5M	14.2M	16.2M
2016	12.2M	12.2M	12.2M	12.4M
2015	11.2M	11.2M	11.9M	12.4M
2014	8.7M	9.5M	10.0M	10.4M
2013	7.8M	7.9M	8.0M	8.1M
2012	6.4M	6.6M	7.2M	7.8M
2011	4.9M	5.3M	5.7M	6.0M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Repro-Med Systems Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	matin shahriar	acquired	14,999	2.37	6,329	-
Mar 31, 2024	wholihan edward	acquired	14,999	2.37	6,329	-
Mar 31, 2024	cascella robert	acquired	14,999	2.37	6,329	-
Mar 31, 2024	manko joseph m. jr.	acquired	-	-	6,329	-
Mar 31, 2024	fletcher r john	acquired	22,498	2.37	9,493	-
Mar 31, 2024	french donna	acquired	14,999	2.37	6,329	-
Mar 13, 2024	tharby linda m	sold (taxes)	-14,826	2.09	-7,094	president and ceo
Mar 13, 2024	tharby linda m	acquired	41,133	2.09	19,681	president and ceo
Feb 16, 2024	manko joseph m. jr.	sold	-	-	-27,700	-
Jan 10, 2024	manko joseph m. jr.	sold	-	-	-453,231	-

Which funds bought or sold KRMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	WASHINGTON TRUST Co	unchanged	-	-9,500	236,000	0.01%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.19	-9,000	3,000	-%
Apr 22, 2024	Lakewood Asset Management LLC	unchanged	-	-5,693	141,423	0.10%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	60,416	60,416	-%
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	reduced	-3.58	-137,941	1,749,600	0.14%
Apr 19, 2024	Advisor Resource Council	new	-	62,603	62,603	0.03%
Apr 19, 2024	Mesirow Financial Investment Management, Inc.	sold off	-100	-26,904	-	-%
Apr 12, 2024	Carlson Capital Management	unchanged	-	-1,425	35,400	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-0.9	-26,135	238,135	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.13	-410,447	4,688,740	-%

Are Funds Buying or Selling KRMD?

Are funds buying KRMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KRMD

No. of Funds

Unveiling Repro-Med Systems Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	first light asset management, llc	11.30%	5,158,444	SC 13G
Feb 13, 2024	archon capital management llc	8.15%	3,720,876	SC 13G/A
Jan 02, 2024	horton capital partners, llc	16.66%	7,609,751	SC 13D/A
Feb 24, 2023	horton capital partners, llc	16.%	7,430,603	SC 13D/A
Feb 14, 2023	first light asset management, llc	13.91%	6,299,771	SC 13G/A
Feb 13, 2023	archon capital management llc	6.56%	2,969,732	SC 13G/A
Feb 14, 2022	archon capital management llc	6.41%	2,856,502	SC 13G
Feb 14, 2022	first light asset management, llc	13.03%	5,807,647	SC 13G/A
Apr 06, 2021	horton capital partners, llc	16.77%	7,459,776	SC 13D/A
Jan 08, 2021	first light asset management, llc	13.36%	5,871,364	SC 13G/A

Recent SEC filings of Repro-Med Systems Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	8-K	Current Report
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 28, 2024	DEF 14A	DEF 14A
Mar 18, 2024	PRE 14A	PRE 14A
Mar 15, 2024	4	Insider Trading

Peers (Alternatives to Repro-Med Systems Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-2.36%	-14.10%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.02%	16.40%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	1.30%	-3.37%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	12.50%	-31.24%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	5.60%	-56.15%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.33	1.07	5.77%	8.23%

Repro-Med Systems Inc News

Latest updates

Repro-Med Systems Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	2.6%	7,185,932	7,003,198	6,935,931	7,392,605	7,344,681	7,760,398	6,546,628	6,244,330	6,490,506	6,040,544	5,528,174	5,430,951	4,057,220	6,080,315	7,708,904	6,330,009	6,222,134	6,617,397	5,348,812	4,974,278	4,271,000
Gross Profit	-0.3%	4,330,946	4,342,177	3,888,124	4,147,035	4,078,146	4,322,362	3,346,173	3,622,305	3,831,790	3,495,750	3,210,184	3,231,854	2,297,273	3,940,723	4,909,880	3,788,210	3,947,284	4,382,908	3,475,664	3,047,954	2,713,512
Operating Expenses	6.4%	6,528,500	6,133,198	7,112,700	7,203,863	6,589,563	5,851,841	6,959,635	6,748,820	5,944,948	4,817,784	4,591,238	5,445,143	3,461,706	3,581,897	5,941,881	3,205,387	4,106,928	3,558,424	3,439,786	3,162,993	3,149,803
S&GA Expenses	8.4%	5,012,645	4,623,928	5,303,167	5,425,877	4,759,923	4,825,349	5,530,022	5,491,213	4,881,710	3,901,830	4,085,945	4,992,829	2,938,750	3,075,169	3,201,831	2,862,138	2,795,060	2,441,381	2,050,435	2,484,868	2,529,685
R&D Expenses	-0.4%	1,287,515	1,293,256	1,596,614	1,564,869	1,641,982	862,148	1,303,731	1,148,355	949,930	800,020	386,878	336,841	352,117	390,416	298,196	256,025	290,021	170,260	178,235	101,959	80,390
EBITDA Margin	4.1%	-0.31	-0.32	-0.31	-0.34	-0.36	-0.34	-0.36	-0.28	-0.25	-0.15	-0.07	-0.05	0.07	-	-	-	-	-	-	-	-
Interest Expenses	9.9%	16,059	14,608	7,839	12,326	12,790	9,496	1,779	4,425	7,047	6,147	19.00	28.00	38.00	14,144	13,467	87.00	62.00	47.00	59.00	174	-
Income Taxes	1913.5%	5,445,122	-300,247	-599,995	-577,400	-434,659	-271,500	-710,260	-597,599	-375,837	-238,104	-245,316	-942,361	-334,000	143,353	30,919	141,928	-57,196	186,681	24,683	-22,099	-71,576
Earnings Before Taxes	-21.1%	-2,020,907	-1,668,509	-3,095,881	-2,988,285	-2,411,386	-1,497,060	-3,631,601	-3,135,113	-1,444,195	-1,331,882	-1,369,865	-2,218,499	1,255,498	392,528	-1,045,119	591,356	-137,453	838,494	102,866	-107,489	-426,709
EBT Margin	3.3%	-0.34	-0.35	-0.34	-0.36	-0.38	-0.36	-0.38	-0.30	-0.27	-0.17	-0.09	-0.07	0.05	-	-	-	-	-	-	-	-
Net Income	-445.7%	-7,466,029	-1,368,262	-2,495,886	-2,410,885	-1,976,727	-1,225,560	-2,921,341	-2,537,514	-1,068,358	-1,093,778	-1,124,549	-1,276,138	-834,628	249,175	-1,076,038	449,428	-80,257	651,813	78,183	-85,390	-355,133
Net Income Margin	-67.4%	-0.48	-0.29	-0.28	-0.29	-0.31	-0.29	-0.30	-0.24	-0.19	-0.21	-0.14	-0.13	-0.05	-	-	-	-	-	-	-	-
Free Cashflow	193.4%	1,096,805	-1,174,838	-248,758	-4,755,404	1,241,643	-2,210,520	-2,968,063	-1,846,893	-811,953	-921,049	-265,318	-2,700,474	-1,806,581	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-19.5%	28.00	35.00	36.00	38.00	42.00	43.00	42.00	43.00	41.00	41.00	41.00	42.00	40.00	45.00	48.00	17.00	14.00	14.00	12.00	12.00	11.00
Current Assets	-6.6%	20.00	22.00	23.00	25.00	30.00	31.00	31.00	34.00	37.00	38.00	37.00	39.00	38.00	43.00	45.00	14.00	12.00	12.00	10.00	10.00	9.00
Cash Equivalents	6.6%	11.00	11.00	12.00	12.00	17.00	16.00	18.00	23.00	25.00	26.00	27.00	27.00	27.00	32.00	38.00	7.00	6.00	5.00	4.00	3.00	4.00
Inventory	-25.6%	3.00	5.00	5.00	7.00	6.00	7.00	7.00	6.00	6.00	7.00	8.00	8.00	7.00	6.00	4.00	3.00	2.00	3.00	3.00	3.00	2.00
Net PPE	0.5%	4.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	2.3%	8.00	8.00	8.00	8.00	11.00	10.00	10.00	9.00	5.00	5.00	3.00	5.00	4.00	5.00	8.00	4.00	3.00	3.00	2.00	2.00	2.00
Current Liabilities	5.5%	4.00	4.00	4.00	5.00	7.00	6.00	6.00	5.00	5.00	5.00	3.00	5.00	4.00	5.00	8.00	4.00	2.00	2.00	2.00	2.00	2.00
Shareholder's Equity	-25.8%	20.00	27.00	28.00	30.00	31.00	32.00	33.00	35.00	37.00	37.00	37.00	38.00	36.00	40.00	39.00	12.00	11.00	11.00	10.00	9.00	9.00
Retained Earnings	-47.1%	-23.31	-15.85	-14.48	-11.98	-9.57	-7.59	-6.37	-3.45	-0.91	0.00	1.00	2.00	4.00	4.00	4.00	5.00	5.00	5.00	4.00	4.00	4.00
Additional Paid-In Capital	0.8%	47.00	47.00	46.00	45.00	44.00	43.00	42.00	42.00	41.00	40.00	39.00	39.00	36.00	35.00	35.00	7.00	6.00	6.00	5.00	5.00	5.00
Accumulated Depreciation	-	3.00	-	-	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.1%	46.00	46.00	46.00	46.00	45.00	45.00	45.00	45.00	45.00	44.00	44.00	44.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	111	-	-	-	72.00	-	-	-	120	-	-	-	212	-	-	-	55.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	193.4%	1,097	-1,174	-153	-4,660	1,336	-2,115	-2,873	-1,752	-717	-826	-170	-2,605	-1,711	-1,739	2,554	153	823	982	-438	-1,045	127
Share Based Compensation	-44.2%	389	698	801	881	718	782	742	838	740	628	605	734	428	406	424	361	308	368	231	298	211
Cashflow From Investing	2.5%	-208	-213	-108	-283	-223	-648	-1,176	-752	-47.68	-151	-64.93	-102	-28.61	-494	-333	-180	-79.07	-143	1,629	-96.83	-2.23
Cashflow From Financing	-140.4%	-178	441	-242	-238	-145	940	-262	-252	-133	673	-813*	2,167	-3,378	-3,462	28,480	1,584	-1.66	483	24.00	-3.85	-35.07
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	-2.82	-

KRMD Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
NET REVENUES	$ 28,517,666	$ 27,896,037
Cost of goods sold	11,809,384	12,527,051
Gross Profit	16,708,282	15,368,986
OPERATING EXPENSES
Selling, general and administrative	20,365,617	20,606,507
Research and development	5,742,254	4,956,215
Depreciation and amortization	870,390	587,137
Total Operating Expenses	26,978,261	26,149,859
Net Operating Loss	(10,269,979)	(10,780,873)
Non-Operating Income
Loss on foreign currency exchange	(5,124)	(39,874)
Loss on disposal of fixed assets	(59,807)
Interest income, net	561,328	145,587
TOTAL OTHER INCOME	496,397	105,713
LOSS BEFORE TAXES	(9,773,582)	(10,675,160)
Income (tax)/benefit	(3,967,480)	2,014,018
NET LOSS	$ (13,741,062)	$ (8,661,142)
NET LOSS PER SHARE
Basic	$ (0.30)	$ (0.19)
Diluted	$ (0.30)	$ (0.19)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic	45,601,346	45,002,074
Diluted	45,601,346	45,002,074

KRMD Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 11,482,240	$ 17,408,257
Accounts receivable less allowance for doubtful accounts of $24,777 and $21,459 for December 31, 2023, and December 31, 2022, respectively	4,045,211	3,558,884
Inventory	3,481,301	6,404,867
Other receivables	28,889	972,396
Prepaid expenses and other	1,218,288	1,457,232
TOTAL CURRENT ASSETS	20,255,929	29,801,636
Property and equipment, net	3,837,657	3,886,975
Intangible assets, net of accumulated amortization of $390,341 and $325,872 at December 31, 2023 and December 31, 2022, respectively	754,361	787,182
Operating lease right-of-use assets	3,514,055	3,786,545
Deferred income tax assets, net allowance for non-realization of deferred tax assets of $6,002,777 and zero for December 31, 2023 and December 31, 2022, respectively		3,967,480
Other assets	98,970	102,625
TOTAL ASSETS	28,460,972	42,332,443
CURRENT LIABILITIES
Accounts payable	975,193	2,391,799
Accrued expenses	1,711,427	2,889,941
Note Payable	314,344	433,295
Other liabilities	512,520	257,337
Accrued payroll and related taxes	462,941	542,399
Finance lease liability – current	109,540	98,335
Operating lease liability – current	368,313	345,834
TOTAL CURRENT LIABILITIES	4,454,278	6,958,940
Finance lease liability, net current portion	316,623	394,283
Operating lease liability, net of current portion	3,336,300	3,653,257
TOTAL LIABILITIES	8,107,201	11,006,480
STOCKHOLDERS’ EQUITY
Common stock, $0.01 par value, 75,000,000 shares authorized, 49,089,864 and 48,861,891 shares issued; 45,669,362 and 45,441,389 shares outstanding at December 31, 2023, and December 31, 2022, respectively	490,899	488,619
Additional paid-in capital	47,018,707	44,252,117
Treasury stock, 3,420,502 shares at December 31, 2023 and December 31, 2022, at cost	(3,843,562)	(3,843,562)
Retained Deficit	(23,312,273)	(9,571,211)
TOTAL STOCKHOLDERS’ EQUITY	20,353,771	31,325,963
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 28,460,972	$ 42,332,443

About Repro-Med Systems Inc

KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the subcutaneous drug delivery market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. The company was incorporated in 1980 and is headquartered in Mahwah, New Jersey.

CEO	Ms. Linda M. Tharby
WEBSITE	korumedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	85

Repro-Med Systems Inc Frequently Asked Questions

What is the ticker symbol for Repro-Med Systems Inc? What does KRMD stand for in stocks?

KRMD is the stock ticker symbol of Repro-Med Systems Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repro-Med Systems Inc (KRMD)?

As of Tue Apr 23 2024, market cap of Repro-Med Systems Inc is 97.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRMD stock?

You can check KRMD's fair value in chart for subscribers.

What is the fair value of KRMD stock?

You can check KRMD's fair value in chart for subscribers. The fair value of Repro-Med Systems Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repro-Med Systems Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repro-Med Systems Inc a good stock to buy?

The fair value guage provides a quick view whether KRMD is over valued or under valued. Whether Repro-Med Systems Inc is cheap or expensive depends on the assumptions which impact Repro-Med Systems Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRMD.

What is Repro-Med Systems Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, KRMD's PE ratio (Price to Earnings) is -7.12 and Price to Sales (PS) ratio is 3.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Repro-Med Systems Inc's stock?

In the past 10 years, Repro-Med Systems Inc has provided 0.251 (multiply by 100 for percentage) rate of return.